Cwm LLC Acquires 17,145 Shares of Exelixis, Inc. $EXEL

Cwm LLC grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,334 shares of the biotechnology company's stock after buying an additional 17,145 shares during the quarter. Cwm LLC owned approximately 0.06% of Exelixis worth $6,626,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Fuller & Thaler Asset Management Inc. lifted its position in Exelixis by 2.2% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company's stock worth $287,794,000 after buying an additional 164,134 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Exelixis by 73.8% during the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company's stock worth $250,869,000 after purchasing an additional 2,926,884 shares during the last quarter. Invesco Ltd. grew its stake in Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company's stock valued at $205,725,000 after buying an additional 1,596,948 shares during the last quarter. Nuveen LLC acquired a new position in Exelixis in the 1st quarter valued at about $123,310,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Exelixis by 2.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company's stock valued at $122,626,000 after buying an additional 69,054 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Up 1.3%

NASDAQ EXEL opened at $40.03 on Thursday. The company has a market capitalization of $10.78 billion, a P/E ratio of 19.25, a P/E/G ratio of 0.79 and a beta of 0.38. Exelixis, Inc. has a 12-month low of $27.86 and a 12-month high of $49.62. The firm has a 50-day moving average price of $38.75 and a two-hundred day moving average price of $39.96.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.12. The firm had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business's revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. Equities analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on EXEL shares. Barclays started coverage on shares of Exelixis in a research note on Wednesday, September 17th. They issued an "equal weight" rating and a $40.00 price target on the stock. Zacks Research lowered shares of Exelixis from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 26th. Stephens upgraded shares of Exelixis from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $29.00 to $60.00 in a research note on Tuesday, June 24th. Royal Bank Of Canada decreased their price target on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating on the stock in a research note on Tuesday, July 29th. Finally, HC Wainwright decreased their price target on shares of Exelixis from $53.00 to $46.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Fifteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Exelixis has a consensus rating of "Moderate Buy" and a consensus target price of $44.42.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.